Welcome on the DDIM-Website of Simone Lorenz-Asmus
Simone Lorenz-Asmus
Organisational development and interim management
Interim executive for organisational development and transformation in pharma, biotech and healthcare. My focus is Europe, the GCC and the USA.
Contact data
Lorenz Asmus Interim Management, Frankfurt
- Telefon Mobile
- +49 1721824463
Social networks
Personal data
- Date of birth
- 06.03.1979 (Age:47)
Short profile
- Change Management
- Building a Company / Business
- Consulting
- Process Optimization
- Internationalization
- Organisationsentwicklung und Transformation
- Post-Merger-Integration
- Vakanzüberbrückung und Geschäftskontinuität
- Research & Development
- Organization
- Operations
- Pharmacovigilance
- Governance, Risk & Compliance (GRC)
- 2nd Level / Division Management / Department Management
- Consultant, Advisor
- Interimsleitung Pharmakovigilanz
- Interimsleitung Transformation
- Vakanzüberbrückung auf Führungsebene
- Pharmaceutical Industry
- Biotech
- Healthcare
- Gesundheitswesen
- Corporation / Group
- Medium-sized Enterprise
- Europe (EU)
- Dubai
- Saudi Arabia
- Switzerland
- USA
- German (Mother tongue)
- English (Business fluent)
- Organisationsentwicklung und Transformation in regulierten Organisationen
- Interim Management auf Führungsebene bei Vakanzen und in Übergangsphasen
- Change Management und Kulturwandel
- Führung globaler und lokaler Teams in mehr als 70 Ländern
- Post-Merger-Integration von Governance, regulatorischen Prozessen und Unternehmenskulturen
- Aufbau globaler und lokaler Pharmakovigilanz-Systeme nach GVP
- Vorbereitung auf Audits und Inspektionen von Behörden wie EMA, FDA, BfArM und SFDA
- Erfahrung als EU-QPPV und Stufenplanbeauftragte
- Organisationsentwicklung und Interim Management im Gesundheitswesen der Golfregion
- Einführung von KI in regulierte Organisationen nach ISO/IEC 42001 und EU AI Act
IM projects (self employed)
Internationales Biotech-Unternehmen
Vaccine manufacturer
- City / place
- Kopenhagen, Dänemark
An internationally operating biotech company faced a critical situation in its regulatory safety organisation.
• need for interim leadership
• vacant EU QPPV position
• upcoming regulatory inspection
• missing oversight
• unclear service provider performance
• pharmacovigilance organisation not inspection-ready
• fragmented processes, few SOPs or policies
• risk of non-compliance in some areas
- Team stabilisation and interim leadership
- EU QPPV role with personal accountability
- Preparing the handover to the successor
- Governance of the PV system and organisational design
- Process analysis and improvement, writing SOPs and policies
- Vendor and service provider oversight
- Inspection preparation
- Stabilisation, coaching, mentoring and professional leadership of the team
- Registration as EU QPPV
- Revision and rebuilding of SOPs and core processes
- Gap analysis, improvement plan and implementation
- Establishment of vendor oversight and service-level control
- Preparation and support of the inspection as EU QPPV
- Risk management
- Regulatory operability in the market maintained
- Team stabilised and given a new direction
- Regulatory accountability without interruption
- New oversight and governance structure implemented
- Documented standards and processes in line with compliance requirements
- Two audits passed successfully
- Team stabilisation especially recognised by the client
- I gave people direction, built trust and showed them that someone was there to take responsibility.
- What had been ongoing chaos became a calm, stable function the team could rely on.
Work history (permanent employment)
CSL Behring
One of the world’s leading manufacturers of life-saving medicines derived from human plasma and related therapies, active in more than 30 countries, with Marburg as its largest site.
- City / place
- Marburg
PV responsibility for EEA, UK and Eastern and Central Intercontinental (ECI), more than 70 countries.
Team of 22, 6 in direct line and 16 safety officers in the matrix. Teams in Dubai and Saudi Arabia.
Post-merger integration of Vifor Pharma and Seqirus into the regional operating model.
Qualification programme for distributors in 20 MEA countries, later a template worldwide.
Introduced digital governance and compliance platforms.
Inspections and audits with EMA, MHRA, BfArM, SFDA and MOHAP.
HORIZON Pharma
Biopharmaceutical company headquartered in Dublin with subsidiaries in Germany, Switzerland and the USA, focused on orphan diseases, primary care and rheumatology.
- City / place
- Mannheim
Built the global PV operations unit and led the PV post-merger integrations, three acquisitions in 18 months.
• Led integration teams, interface between acquirer and target
• Created and executed pre- and post-merger integration plans
• Change management
• Integration of PV systems and safety databases
• Global team with staff in the USA and Germany
• Standard processes under GVP, SOPs, oversight of PV service providers
• Represented PV in audits and inspections
Merck KGaA
Global group headquartered in Darmstadt, the world's oldest pharmaceutical and chemical company, with Healthcare, Life Science and Performance Materials businesses.
- City / place
- Darmstadt
Supported the drug safety teams in affiliates and regional hubs, with a focus on global process standardisation and PV governance for Europe, MEA, APAC and the USA.
• Developed and implemented SOPs
• Defined requirements for a drug safety database solution together with IT
• Processed safety information from systematic data collections
• Global Process Owner GVP
• Improved PV compliance in preparation for inspections
Merz Pharmaceuticals GmbH
International healthcare company with its own research and development, focused on aesthetic dermatology and specialty neurology, with more than 2,400 employees in the group.
- City / place
- Frankfurt
Senior Drug Safety Associate, from 2012 Senior Pharmacovigilance Manager, from 2014 Senior Manager Business Processes.
• Process analysis, improvement and definition in the PV system, SOPs, work instructions and training
• Built the medical device vigilance system and developed the global medical device vigilance strategy
• Monitored global compliance and rolled the strategy out to affiliates and third parties
• Built a training system
Education
Frankfurt School of Finance & Management, Frankfurt am Main
Vier Module: Organisationsstrukturen verstehen, neu denken und verändern; Kernprozesse der Organisationsentwicklung; Managing & Leading Change; Transformation in der Praxis, Kultur, Macht und nachhaltige Veränderung. Abschluss voraussichtlich Februar 2027.
Friedrich-Alexander-Universität Erlangen-Nürnberg, Nürnberg
Wahlmodul Pharmazeutische Industrie, Masterarbeit zu Outsourcing in der pharmazeutischen Industrie. Zusatzmodul Ambient Assisted Living.
SRH University of Applied Sciences Heidelberg
Abschluss als Diplom-Betriebswirtin (FH). Diplomarbeit zur Versorgung von Menschen mit Demenz an der Schnittstelle von Kranken- und Pflegeversicherung.
Krankenpflegeschule der Frankfurter Diakonie-Kliniken, Frankfurt am Main
Staatliche Erlaubnis zur Führung der Berufsbezeichnung Krankenschwester, Regierungspräsidium Darmstadt, 2001.